Clinical relevance of shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome

Pediatric Infectious Disease Journal

Volumn 30, Issue 6, 2011, Pages 486-490

  Brigotti, Maurizio ^a   Tazzari, Pier Luigi ^b   Ravanelli, Elisa ^a   Carnicelli, Domenica ^a   Rocchi, Laura ^a   Arfilli, Valentina ^a   Scavia, Gaia ^c   Minelli, Fabio ^c   Ricci, Francesca ^b   Pagliaro, Pasqualepaolo ^b   Ferretti, Alfonso V S ^d   Pecoraro, Carmine ^d   Paglialonga, Fabio ^e   Edefonti, Alberto ^e   Procaccino, Maria Antonietta ^f   Tozzi, Alberto E ^f   Caprioli, Alfredo ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

acute renal failure; hemolytic uremic syndrome; neutrophils; Shiga toxin producing Escherichia coli; Shiga toxins

Indexed keywords

SHIGA TOXIN;

ACUTE KIDNEY FAILURE; ARTICLE; BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CYTOFLUOROMETRY; CYTOTOXICITY TEST; ENDOTHELIUM CELL; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFANT; KIDNEY DYSFUNCTION; MALE; NEUTROPHIL; PRESCHOOL CHILD; PRIORITY JOURNAL; SHIGA TOXIN PRODUCING ESCHERICHIA COLI;

EID: 79958010566     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182074d22     Document Type: Article

References (39)

1. Trompeter RS, Schwartz R, Chantler C, et al. Haemolytic-uraemic syndrome: an analysis of prognostic features. Arch Dis Child. 1983;58:101-105. (Pubitemid 13152859)
2. Griffin PM, Tauxe RV. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic Ecoli, and the associated hemolytic uremic syndrome. Epidemiol Rev. 1991;13:60-98.
3. Karmali MA, Petric M, Lim C, et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis. 1985;151:775-782. (Pubitemid 15094592)
4. Tozzi AE, Caprioli A, Minelli F, et al. Shiga toxin-producing Escherichia coli infections associated with hemolytic uremic syndrome, Italy, 1988-.2000. Emerg Infect Dis. 2003;9:106-108. (Pubitemid 36110210)
5. Caprioli A, Morabito S, Brugere H, et al. Enterohaemorrhagic Escherichia coli: emerging issues on virulence and modes of transmission. Vet Res. 2005;36:289-311. (Pubitemid 40716367)
6. Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev. 1998;11:450-479. (Pubitemid 28379095)
7. Ray PE, Liu XH. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr Nephrol. 2001;16:823-839. (Pubitemid 32895613)
8. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16:1035-1050. (Pubitemid 41710314)
9. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev. 1998;11:142-201. (Pubitemid 28046019)
10. Acheson DW, Moore R, De Breucker S, et al. Translocation of Shiga toxin across polarized intestinal cells in tissue culture. Infect Immun. 1996;64: 3294-3300. (Pubitemid 26256179)
11. Hurley BP, Thorpe CM, Acheson DW. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun. 2001;69:6148-6155. (Pubitemid 32885176)
12. Malyukova I, Murray KF, Zhu C, et al. Macropinocytosis in Shiga toxin 1 uptake by human intestinal epithelial cells and transcellular transcytosis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G78-G92.
13. Caprioli A, Luzzi I, Rosmini F, et al. The HUS Italian Study Group. Hemolytic-uremic syndrome and Vero cytotoxin-producing Escherichia coli infection in Italy. J Infect Dis. 1992;166:154-158.
14. Flagler MJ, Strasser JE, Chalk CL, et al. Comparative analysis of the abilities of Shiga toxins 1 and 2 to bind to and influence neutrophil apoptosis. Infect Immun. 2007;75:760-765. (Pubitemid 46203438)
15. Griener TP, Mulvey GL, Marcato P, et al. Differential binding of Shiga toxin 2 to human and murine neutrophils. J Med Microbiol. 2007;56:1423-1430. (Pubitemid 350175065)
16. te Loo DM, Monnens LA, van Der Velden TJ, et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood. 2000;95:3396-3402. (Pubitemid 30428469)
17. Tazzari PL, Ricci F, Carnicelli D, et al. Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome. Cytometry B Clin Cytom. 2004;61:40-44. (Pubitemid 39223369)
18. Brigotti M, Carnicelli D, Ravanelli E, et al. Interactions between Shiga toxins and human polymorphonuclear leukocytes. J Leukoc Biol. 2008;84: 1019-1027.
19. Brigotti M, Caprioli A, Tozzi AE, et al. Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic-uremic syndrome. J Clin Microbiol. 2006;44:313-317. (Pubitemid 43222215)
20. Te Loo DM, van Hinsbergh VW, van den Heuvel LP, et al. Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J Am Soc Nephrol. 2001;12:800-806. (Pubitemid 32246708)
21. Brigotti M, Alfieri R, Sestili P, et al. Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells. FASEB J. 2002;16:365-372. (Pubitemid 34195297)
22. Nakao H, Takeda T. Escherichia coli Shiga toxin. J Nat Toxins. 2000;9: 299-313.
23. Zoja C, Angioletti S, Donadelli R, et al. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int. 2002;62:846-856. (Pubitemid 35316713)
24. Matussek A, Lauber J, Bergau A, et al. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. Blood. 2003;102:1323-1332. (Pubitemid 36988039)
25. Brigotti M, Carnicelli D, Ravanelli E, et al. Molecular damage and induction of proinflammatory cytokines in human endothelial cells exposed to Shiga toxin 1, Shiga toxin 2, and alpha-sarcin. Infect Immun. 2007;75: 2201-2207. (Pubitemid 46744306)
26. Persson S, Olsen KE, Ethelberg S, et al. Subtyping method for Escherichia coli Shiga toxin (verocytotoxin) 2 variants and correlations to clinical manifestations. J Clin Microbiol. 2007;45:2020-2024. (Pubitemid 46933951)
27. Friedrich AW, Bielaszewska M, Zhang WL, et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis. 2002;185:74-84. (Pubitemid 34043019)
28. Brigotti M, Tazzari PL, Ravanelli E, et al. Endothelial damage induced by Shiga toxins delivered by neutrophils during transmigration. J Leukoc Biol. 2010;88:201-210.
29. Gianviti A, Tozzi AE, De Petris L, et al. Risk factors for poor renal prognosis in children with hemolytic uremic syndrome. Pediatr Nephrol. 2003;18:1229-1235. (Pubitemid 37527096)
30. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073-1086. (Pubitemid 40386785)
31. Caprioli A, Luzzi I, Gianviti A, et al. Pheno-genotyping of verotoxin 2 (VT2)-producing Escherichia coli causing haemorrhagic colitis and haemolytic uraemic syndrome by direct analysis of patients' stools. J Med Microbiol. 1995;43:348-353.
32. Caprioli A, Luzzi I, Rosmini F, et al. Community-wide outbreak of hemolytic-uremic syndrome associated with non-O157 verocytotoxin-producing Escherichia coli. J Infect Dis. 1994;169:208-211.
33. Petronini PG, Tramacere M, Mazzini A, et al. Hyperosmolarity-induced stress proteins in chick embryo fibroblasts. Exp Cell Res. 1987;172:450-462. (Pubitemid 18025347)
34. Maier JA, Voulalas P, Roeder D, et al. Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer. Science. 1990;249:1570-1574.
35. Ryd M, Alfredsson H, Blomberg L, et al. Purification of Shiga toxin by alpha-D-galactose-(1-4)-beta-D-galactose-(1-4)-beta-D-glucose-(1-) receptor ligand-based chromatography. FEBS Lett. 1989;258:320-322. (Pubitemid 20001079)
36. Downes FP, Barrett TJ, Green JH, et al. Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies. Infect Immun. 1988;56:1926-1933.
37. Gerber A, Karch H, Allerberger F, et al. Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis. 2002;186:493-500. (Pubitemid 34876258)
38. Geelen JM, van der Velden TJ, Te Loo DM, et al. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shigalike toxin 2 antibody with human polymorphonuclear leucocytes. Nephrol Dial Transplant. 2007;22:749-755. (Pubitemid 46351681)
39. Taylor FB Jr, Tesh VL, DeBault L, et al. Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol. 1999;154:1285-1299. (Pubitemid 29169762)